Menu
  • Join
  • Login
  • Contact
 

Search abstracts


The efficacy and safety of zepatier treatment experience in hcv genotype 1 patients

  • At: 2018 FIP Congress in Glasgow (Scotland)
  • Type: Poster
  • By: TSAI, Tzu-Cheng (Chang Gung Memorial Hospital, Department of pharmacy)
  • Co-author(s): Tzu-Cheng Tsai
    Shin-Tarng Deng
    Chao-Wei Hsu
  • Abstract:

    Background

    Zepatier (elbasvir and grazoprevir) is a directly acting antivirals (DAA) for treatment of chronic HCV genotype (GT) 1 or 4 infection in adults. It was approved by TFDA since Dec. 2016, then reimbursement for fibrosis 3 or 4 (F3 or 4) by NHI since Aug. 2017. Approximately 53% of HCV infected patients were genotype 1 in Taiwan, DAA was..

  • The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress. Please login
Last update 4 October 2019

FIP Congresses